[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592418":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":16,"studyPopulation":16,"armGroups":24,"interventions":33,"overallOfficials":16,"centralContacts":38,"locations":48,"responsibleParty":63,"collaborators":16,"id":65,"slug":16,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":16,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":72,"minAge":73,"maxAge":16,"enrollmentInfo":74,"targetDuration":16,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":16,"overallStatus":83,"whyStopped":16,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Dong-A ST Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":16},[9,13],{"measure":10,"description":11,"timeFrame":12},"AUCt","area under the curve","pre-dose~72 hours post-dose",{"measure":14,"description":15,"timeFrame":12},"Cmax","maximum plasma concentration",null,{"allocation":18,"interventionModel":19,"interventionModelDescription":20,"primaryPurpose":21,"observationalModel":16,"timePerspective":16,"maskingInfo":22},"RANDOMIZED","CROSSOVER","DA-5222","TREATMENT",{"masking":23,"maskingDescription":16,"whoMasked":16},"NONE",[25,30],{"label":26,"type":27,"description":16,"interventionNames":28},"Sequence A","EXPERIMENTAL",[29],"Drug: DA-5222",{"label":31,"type":27,"description":16,"interventionNames":32},"Sequence B",[29],[34],{"type":35,"name":20,"description":36,"armGroupLabels":37,"otherNames":16},"DRUG","single dose administration (DA-5222 one tablet once a day)",[26,31],[39,44],{"name":40,"role":41,"phone":42,"phoneExt":16,"email":43},"Jihyun Sung","CONTACT","+82-02-920-8369","jhsung@donga.co.kr",{"name":45,"role":41,"phone":46,"phoneExt":16,"email":47},"Heechan Jung","+82-02-920-8322","hcjung@donga.co.kr",[49],{"facility":50,"status":16,"city":51,"state":52,"zip":16,"country":52,"countryCode":16,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Bumin Hospital","Seoul","South Korea",{"type":54,"coordinates":55},"Point",[56,57],126.9784,37.566,{"lat":57,"lon":56},[60],{"name":61,"role":41,"phone":16,"phoneExt":16,"email":62},"Taegon Hong, Ph.D","tghong@bumin.co.kr",{"type":64,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR","100592418",false,"NCT06993168","To Evaluate Effect of Food of DA-5222 in Healthy Adult Subjects","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Phase 1 Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics of DA-5222 in Healthy Adult Subjects","Inclusion Criteria:\n\n* Healthy volunteers\n* BMI between 18 and 30 kg\u002Fm2\n* Body weight: Male≥50kg, Female≥45kg\n* Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study\n\nExclusion Criteria:\n\n* Subjects with clinically significant medical history\n* Subjects with history of drug abuse or addicted\n* Subjects with allergy or drug hypersensitivity",true,"ALL","19 Years",{"count":75,"type":76},32,"ESTIMATED","INTERVENTIONAL",[79],"PHASE1","This study is to evaluate the effect of food on pharmacokinetics of DA-5222 in healthy adult subjects",[82],"Healthy","NOT_YET_RECRUITING","2025-05-19",{"date":86,"type":87},"2025-05-28","ACTUAL",{"date":89,"type":76},"2025-05-21",{"date":91,"type":76},"2025-07",{"name":5,"class":6},1]